Dr Maughan on the Need for Consensus on Treatment Intensification in mHSPC

Benjamin L. Maughan, MD, PharmD, an associate professor in the Division of Medical Oncology at Huntsman Cancer Institute of University of Utah Health, discussed the slow uptake of treatment intensification beyond androgen deprivation therapy (ADT) alone in the management of metastatic hormone-sensitive prostate cancer (mHSPC).

Although intensified treatment in this setting has gained traction in recent years, Maughan explained that a gap remains in clinical practice. Creating a broader consensus for treatment intensification in this setting could allow a greater proportion of patients to benefit from a treatment beyond ADT alone, he said.

Maughan led a session on personalizing treatment approaches for patients with mHSPC at the 2025 Bridging the Gaps in Prostate Cancer meeting.